ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Oxnard on Delaying Second-Line Treatment in EGFR-Mutant Lung Cancer

Geoffrey R. Oxnard, MD
Published: Monday, Nov 09, 2015



Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

A lot of lung cancer patients that are identified as having acquired resistance to an EGFR-inhibitor are asymptomatic, says Oxnard. While it may be determined that a patient has progressed based lesion growth by a radiation oncologist, it is possible that a patient may be able to stay on their first-line treatment after this growth and still see benefit.

Waiting a couple more months before starting second-line therapy can allow patients to delay the toxicities that come with chemotherapy, and allow the oncologist to determine the best action plan for their treatment, says Oxnard.

<<< View more from the 2015 NY Lung Cancer Symposium



Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

A lot of lung cancer patients that are identified as having acquired resistance to an EGFR-inhibitor are asymptomatic, says Oxnard. While it may be determined that a patient has progressed based lesion growth by a radiation oncologist, it is possible that a patient may be able to stay on their first-line treatment after this growth and still see benefit.

Waiting a couple more months before starting second-line therapy can allow patients to delay the toxicities that come with chemotherapy, and allow the oncologist to determine the best action plan for their treatment, says Oxnard.

<<< View more from the 2015 NY Lung Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x